Viosera Therapeutics is a pre-clinical drug development company focused on using AI to predict and block drug resistance in cancer and bacteria
Viosera Therapeutics is a pre-clinical drug development company focused on using AI to predict and block drug resistance in cancer and bacteria. Their flagship drug, VT1, targets MRSA using a combination of FDA-approved antibiotics.